Timber Creek Capital Management LLC Acquires 4,336 Shares of Revvity, Inc. (NYSE:RVTY)

Timber Creek Capital Management LLC lifted its position in Revvity, Inc. (NYSE:RVTY - Free Report) by 15.2% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 32,795 shares of the company's stock after purchasing an additional 4,336 shares during the period. Timber Creek Capital Management LLC's holdings in Revvity were worth $4,190,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Assenagon Asset Management S.A. increased its position in shares of Revvity by 3,171.3% during the second quarter. Assenagon Asset Management S.A. now owns 87,180 shares of the company's stock worth $9,142,000 after purchasing an additional 84,515 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Revvity by 27.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 84,383 shares of the company's stock valued at $8,790,000 after buying an additional 18,367 shares in the last quarter. Artemis Investment Management LLP lifted its stake in Revvity by 21.3% in the 2nd quarter. Artemis Investment Management LLP now owns 107,634 shares of the company's stock valued at $11,287,000 after buying an additional 18,916 shares in the last quarter. Bretton Capital Management LLC acquired a new stake in Revvity in the 3rd quarter valued at about $1,405,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Revvity by 76.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,568 shares of the company's stock valued at $3,205,000 after acquiring an additional 13,283 shares during the last quarter. Institutional investors own 86.65% of the company's stock.

Insider Buying and Selling at Revvity

In other news, insider Tajinder S. Vohra sold 2,153 shares of the firm's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $122.09, for a total transaction of $262,859.77. Following the completion of the transaction, the insider now owns 23,960 shares in the company, valued at approximately $2,925,276.40. This trade represents a 8.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

RVTY has been the subject of a number of recent analyst reports. Raymond James raised their price target on shares of Revvity from $144.00 to $146.00 and gave the stock an "outperform" rating in a report on Tuesday, November 5th. Sanford C. Bernstein decreased their price target on shares of Revvity from $150.00 to $145.00 and set an "outperform" rating for the company in a research report on Tuesday, November 5th. Robert W. Baird lifted their price objective on shares of Revvity from $136.00 to $138.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 5th. TD Cowen lifted their price target on shares of Revvity from $141.00 to $144.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Finally, Wells Fargo & Company started coverage on shares of Revvity in a research note on Tuesday, August 27th. They set an "equal weight" rating and a $130.00 price target on the stock. Seven research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $131.73.

Revvity Stock Down 0.1 %

Shares of RVTY stock traded down $0.09 on Friday, hitting $116.14. The stock had a trading volume of 389,640 shares, compared to its average volume of 1,099,678. The stock's 50 day moving average is $119.71 and its 200-day moving average is $116.03. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.97 and a current ratio of 3.56. Revvity, Inc. has a 52-week low of $87.58 and a 52-week high of $129.50. The firm has a market capitalization of $14.13 billion, a price-to-earnings ratio of 56.11, a P/E/G ratio of 3.57 and a beta of 1.05.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $1.28 earnings per share for the quarter, topping analysts' consensus estimates of $1.13 by $0.15. Revvity had a net margin of 9.34% and a return on equity of 7.42%. The business had revenue of $684.10 million for the quarter, compared to analysts' expectations of $679.66 million. During the same quarter last year, the company earned $1.18 EPS. The company's revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, research analysts expect that Revvity, Inc. will post 4.85 earnings per share for the current year.

Revvity declared that its Board of Directors has approved a stock repurchase program on Monday, November 4th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to purchase up to 6.5% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

Revvity Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 7th. Shareholders of record on Friday, January 17th will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, January 17th. This represents a $0.28 annualized dividend and a yield of 0.24%. Revvity's payout ratio is 13.53%.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.